within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR10_LopinavirAndRitonavir;

model LopinavirAndRitonavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AR10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lopinavir and ritonavir is a fixed-dose combination of antiretroviral drugs used in the treatment and prevention of HIV/AIDS. Lopinavir inhibits the HIV-1 protease, while ritonavir acts mainly as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A-mediated metabolism of lopinavir, thereby increasing lopinavir plasma concentrations. This combination is approved and is a common part of highly active antiretroviral therapy (HAART) regimens used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects (both sexes) after oral administration of lopinavir/ritonavir 400 mg/100 mg twice daily in tablet formulation.</p><h4>References</h4><ol><li><p>Lê, MP, et al., &amp; Timsit, JF (2020). Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>The Journal of antimicrobial chemotherapy</i> 75(9) 2657–2660. DOI:<a href=\"https://doi.org/10.1093/jac/dkaa261\">10.1093/jac/dkaa261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32688374/\">https://pubmed.ncbi.nlm.nih.gov/32688374</a></p></li><li><p>Kaufmann, P, et al., &amp; Dingemanse, J (2015). Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. <i>British journal of clinical pharmacology</i> 80(4) 670–677. DOI:<a href=\"https://doi.org/10.1111/bcp.12650\">10.1111/bcp.12650</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25851691/\">https://pubmed.ncbi.nlm.nih.gov/25851691</a></p></li><li><p>Zhang, C, et al., &amp; Denti, P (2012). Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. <i>Antiviral therapy</i> 17(1) 25–33. DOI:<a href=\"https://doi.org/10.3851/IMP1915\">10.3851/IMP1915</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22267466/\">https://pubmed.ncbi.nlm.nih.gov/22267466</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LopinavirAndRitonavir;
